Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.68 |
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | PABPC1 | P11940 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27954455 | 0.84 | KMT2A (0.69) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL31129249 | 0.83 | KMT2A (0.67) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL10404298 | 0.83 | KMT2A (0.67) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL50309 | 0.83 | KMT2A (0.67) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL3761569 | 0.83 | KMT2A (0.68) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL27954458 | 0.83 | KMT2A (0.68) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL27954436 | 0.81 | KMT2A (0.62) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL27954485 | 0.81 | NPC1 (0.63) | KMT2AMEN1PABPC1POLBMAPT | |
| SCHEMBL22773569 | 0.81 | KMT2A (0.65) | KMT2AMEN1PABPC1POLBMAPT | |
| Hydrochloric Acid SCHEMBL38658753 | 0.81 | KMT2A (0.66) | KMT2AMEN1PABPC1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101022810-A | Novel biaromatic compounds which activate peroxisome proliferator activated receptor-like receptors and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2007-08-22 | — | — | CN | claimed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008006563-A1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | KMT2A 4032/4885MEN1 3817/4885PABPC1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.